CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Investing.com - Citizens a réitéré sa notation "Market Outperform" pour CRISPR Therapeutics (NASDAQ:CRSP) avec un objectif de cours de 86,00$, représentant une prime de 51% par rapport au cours actuel ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

GNT est le portail Hi-Tech français consacré aux nouvelles technologies (internet, logiciel, matériel, mobilité, entreprise) et au jeu vidéo PC et consoles.

Chardan Research est positif et recommande le titre à l'achat. L'objectif de cours est modifié à la baisse et désormais fixé à 74 USD contre 82 USD auparavant.

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.